Table 4 Comparison of patients with GL and PL
From: Impact of lipodystrophy on health-related quality of life: the QuaLip study
|  | Baseline (V1) (n = 67) | Year-2 (V9) (n = 56) | ||||
|---|---|---|---|---|---|---|
GL (n = 16) (n = 16) | PL (n = 51) (n = 51) | p value | GL (n = 13) (n = 13) | PL (n = 43) (n = 43) | p value | |
Age (years) | 25 (23–30) | 42 (32–53) |  < 0.001 | 27 (24–30) | 44 (35–55) |  < 0.001 |
Weight (kg) | 52 (51–68) | 60 (53–71) | 0.180 | 57 (50–72) | 66 (56–73) | 0.177 |
BMI (kg/m2) | 20.31 (19.45–22.63) | 23.62 (20.57–27.12) | 0.022 | 21.04 (18.37–24.56) | 24.17 (22.06–27.74) | 0.021 |
Family history | 9 (60.0%) | 23 (53.5%) | 0.662 | NA | NA | NA |
Diabetes | 15 (93.8%) | 46 (90.2%) | 1.000 | 11 (84.6%) | 37 (86.0%) | 1.000 |
Hypertriglyceridemia | 12 (75.0%) | 30 (75.0) | 1.000 | 6 (66.7%) | 14 (70.0%) | 1.000 |
Antidiabetics | 8 (50.0%) | 30 (58.8%) | 0.534 | 6 (37.5%) | 30 (58.8%) | 0.136 |
Insulin | 12 (75.0%) | 24 (47.1%) | 0.051 | 6 (37.5%) | 22 (43.1%) | 0.690 |
Triglyceride lowering drugs | 11 (68.8%) | 18 (35.3%) | 0.018 | 6 (37.5%) | 17 (33.3%) | 0.759 |
HbA1c (%) | 8.3 (6.2–9.5) | 7.2 (6.0–8.1) | 0.120 | 6.8 (6.2–8.4) | 6.3 (5.6–7.9) | 0.449 |
FBG (mg/dL) | 138 (87–170) | 122 (96–171) | 0.847 | 111 (98–116) | 128 (94–190) | 0.824 |
Triglyceride (mg/dL) | 317 (187–457) | 222 (155–465) | 0.537 | 475 (144–594) | 195 (132–398) | 0.532 |
LDL (mg/dL) | 93 (70–101) | 116 (95–131) | 0.047 | 73 (57–101) | 93 (77–130) | 0.180 |
HDL (mg/dL) | 28 (24–35) | 37 (32–46) | 0.007 | 30 (24–68) | 33 (27–50) | 0.973 |
Leptin (ng/dl) | 0.16 (0.10–0.61) | 4.73 (1.25–11.69) |  < 0.001 | 3.04 (1.12–30.44) | 3.89 (1.52–8.73) | 0.643 |
ALT (U/L) | 28 (20–44) | 27 (18–41) | 0.463 | 20 (12–32) | 18 (15–22) | 0.638 |
SF36_PF | 80.00 (45.00–80.00) | 70.00 (45.00–90.00) | 0.504 | 65.00 (40.00–100.00) | 60.00 (35.00–90.00) | 0.380 |
SF36_RP | 37.50 (0.00–75.00) | 50.00 (0.00–100.00) | 0.526 | 100.00 (0.00–100.00) | 100.00 (0.00–100.00) | 0.722 |
SF36_RE | 16.67 (0.00–66.67) | 66.67 (0.00–100.00) | 0.091 | 100.00 (0.00–100.00) | 100.00 (0.00–100.00) | 0.703 |
SF36_VT | 30.00 (28.75–70.00) | 55.00 (35.00–67.50) | 0.404 | 60.00 (40.00–65.00) | 45.00 (30.00–70.00) | 0.726 |
SF36_MH | 52.00 (40.00–63.00) | 56.00 (41.00–72.00) | 0.418 | 64.00 (40.00–72.00) | 56.00 (40.00–68.00) | 1.000 |
SF36_SF | 62.50 (43.75–100.00) | 75.00 (37.50–87.50) | 0.879 | 75.00 (50.00–100.00) | 62.50 (37.50–87.50) | 0.524 |
SF36_BP | 51.50 (22.00–79.00) | 52.00 (41.00–84.00) | 0.499 | 74.00 (52.00–100.00) | 62.00 (36.50–84.00) | 0.295 |
SF36_GH | 32.00 (21.00–48.50) | 37.00 (23.50–62.00) | 0.461 | 47.00 (25.00–62.00) | 35.00 (20.00–57.00) | 0.431 |
Beck Depression Score | 17 (10–23) | 14 (7–24) | 0.503 | 9 (3–25) | 13 (6–26) | 0.607 |
EQ-5D-5L index value | 0.68 (0.31–0.80) | 0.68 (0.30–0.84) | 0.871 | 0.75 (0.55–0.91) | 0.69 (0.29–0.82) | 0.326 |
EQ-5D-5L VAS | 70.00 (40.00–76.25) | 75.00 (57.50–90.00) | 0.156 | 80.00 (60.00–85.00) | 60.00 (45.00–80.00) | 0.192 |
Facit Fatigue Score | 26.50 (16.50–29.75) | 27.00 (18.00–39.50) | 0.373 | 42.00 (23.00–45.00) | 24.00 (17.00–45.00) | 0.466 |